We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Test Identifies Esophageal Cancer Patients Resistant to Chemoradiation Therapy

By LabMedica International staff writers
Posted on 12 Nov 2014
Print article
Image: Histological micrograph of esophageal adenocarcinoma from an endoscopic mucosal resection (Photo courtesy of Nephron).
Image: Histological micrograph of esophageal adenocarcinoma from an endoscopic mucosal resection (Photo courtesy of Nephron).
A proprietary multianalyte test is able to identify which esophageal cancer patients are unlikely to benefit from the standard presurgical treatment of chemoradiation.

The results from a study suggests that up to 30% of esophageal cancer patients may not benefit from the highly toxic, presurgical chemoradiation therapy (CTRT), and instead could have the option of moving directly to surgery and to other treatment options.

The test, called the DecisionDx-EC test (Castle Bioscience; Friendswood, TX, USA) analyzes the localization of three protein biomarkers, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), glioblastoma GLI family zinc finger 1 (Gli1), and sonic hedgehog (SHH), to classify tumors as either responsive to (non-exCTRT) or resistant to CTRT (exCTRT). The test was performed on formalin-fixed paraffin-embedded esophageal cancer tissue.

A study involving 167 patient cases, all of whom underwent a chemoradiation regimen involving 5-fluorouracil (5FU) plus platinum/taxanes showed a specificity of 90% and positive predictive values (PPV) of 64% and negative predictive values (NPV) of 98%. In a second, multicenter validation study involving 64 patient cases, 67% of whom had been treated with a regimen that included 5FU, investigators reported 95% specificity, with a PPV of 88% and a NPV of 83%.

In a parallel study to assess the ability of two preliminary gene signatures to predict responsiveness to chemoradiation therapy in tumor samples from 16 patients, a gene expression profile (GEP) test in development was used for esophageal cancer. The results from this initial study showed that the GEP test predicted treatment response with high accuracy and specificity of 100% and 100%, respectively. The company plans to further evaluate the GEP test in esophageal and rectal cancer.

Sunil Badve, MD, FRCPath, a professor of Pathology and Laboratory Medicine, said, “The standard of care for esophageal cancer, which includes presurgical chemoradiation to reduce tumor bulk prior to surgical resection, is not effective for up to 30% of patients. The ability to identify those patients least likely to benefit from the therapy is an important advancement in managing a patient's disease, allowing them to avoid the toxicities and the delay of surgery and more effective approaches.” The study was presented at the 11th Annual Meeting of the International Society of Gastrointestinal Oncology held October 23–24, 2014, in Arlington (VA, USA).

Related Links:

Castle Bioscience 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.